
The COVID-19 antiviral ensitrelvir (Xocova), was recently approved by the Food and Drug Administration. The oral drug was approved as PEP, or post-exposure prophylaxis, meaning it is taken within 72 hours after coming in contact with someone who has COVID-19.

More research articles

More research updates


We spoke with the two organizations behind the viral moment where advocates interrupted speakers at the Long COVID EU Project event.

A specific formula of probiotics and bacteria was found to improve fatigue and other symptoms in people with Long COVID. Researchers shared the abstract, which has not been published yet, at the Digestive Disease Week meeting in Chicago, Illinois.

The written memorials of over 500 people who had myalgic encephalomyelitis (ME) were analyzed in a new study in PLoS One. Researchers found themes of clinical neglect and broad institutional failure, among others.

A new RECOVER study found that Long COVID significantly impacts the development of children with the disease. The study was published in Academic Pediatrics and included nearly 2,000 children.

A new report found that Long COVID may cost OECD international economies over $135 billion per year over the next decade. And even this number may be an undercount, the authors stated.
advocacy arts CDC clinical trials commentary COVID-19 precautions disability essay government policy H5N1 healthcare HHS influenza international Long COVID in children masks and respirators ME ME/CFS medical education national COVID-19 trends NIH NIH RECOVER podcast public health research update science Trump administration updates and events vaccines wastewater surveillance